Hansa Biopharma AB (publ)
0RC7.L
London Stock Exchange84.70
SEK
-19.80
- -
Hansa Biopharma AB (publ)
0RC7.L
(London Stock Exchange)
Recent
price
84.70
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Hansa Biopharma AB (publ) is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative immunomodulatory enzyme therapies for rare immunological conditions, including transplant rejection, autoimmune diseases, gene therapy, and oncology. The company offers Idefirix (imlifidase), a first-generation enzyme that rapidly inactivates immunoglobulin G (IgG) antibodies via single intravenous administration for desensitizing highly sensitized adult kidney transplant patients with positive crossmatch tests; HNSA-5487, a next-generation enzyme enabling short-term repeat dosing to extend IgG-free windows; and an expanding pipeline of clinical and preclinical programs evaluating these enzymes across multiple indications. Hansa Biopharma, founded in 2007 and headquartered in Lund, Sweden, maintains operations in Europe and the United States, with its ordinary shares listed on Nasdaq Stockholm. In recent developments, the company reports strong Idefirix sales growth of 76% in Q2 2025 versus the prior year, alongside a directed share issue raising approximately USD 24.3 million and debt restructuring with NovaQuest involving USD 14.9 million offset through new shares; imlifidase met its primary endpoint in the pivotal US Phase 3 ConfIdeS trial for kidney transplantation, paving the way for a planned Biologics License Application submission to the FDA; and first clinical data confirmed imlifidase's ability to reduce anti-AAV antibodies, supporting its use as pretreatment in gene therapy, with additional positive results from the GNT-018-IDES trial in Crigler-Najjar syndrome patients.